Literature DB >> 25302189

Ratio Of Serum Asymmetric Dimethyl Arginine (ADMA)/ Nitric Oxide in Coronary Artery Disease patients.

Rajni Rajendra Shivkar1, Subodhini Anant Abhang2.   

Abstract

BACKGROUND: Coronary artery disease (CAD) is the leading cause of mortality and morbidity in the world. Current predictions estimate that by the year 2020 cardiovascular diseases, notably atherosclerosis will become the leading global cause of the total disease burden. Atherosclerosis of the Coronary artery causes myocardial infarction and angina pectoris. Endothelial Nitric oxide (NO), released by the intact and healthy endothelium plays a very important role in the maintenance of vascular tone and structure. Decreased NO level leads to endothelial dysfunction is an initial event in the atherosclerosis. Endogenous Asymmetric dimethylarginine (ADMA) is a structural analog of L-arginine, competitively inhibits the enzyme NO synthase and thus decreases the NO level. AIM: To study the ratio of serum ADMA / NO as a marker of severity of CAD.
MATERIALS AND METHODS: The study comprises of 60 patients of CAD diagnosed by coronary angiography. We divided them into two Groups according to percentage of atherosclerotic block, Group A (71% and more block, n=30) and Group B (40% - 70% block, n=30). We measured serum ADMA, serum NO and calculated ADMA/ NO ratio. RESULTS were compared with 30 healthy age and sex matched controls. Serum ADMA was determined by reverse phase high performance liquid chromatography. Serum NO was measured by cadmium reduction method. Statistical analysis of data analysis was done using the SPSS (Statistical Package for the Social Science) Version 11 for window.
RESULTS: Serum ADMA was correlated positively with the presence and severity of CAD and inversely related with the serum NO levels. Serum ADMA / NO ratio was statistically significant in CAD patients with atherosclerotic block 71% and above (Group A) but ratio was not significant in Group B (block 40% - 70%).
CONCLUSION: Serum ADMA/ NO ratio can be the better predictive marker for the severity of the CAD where patient is at the risk of angina pectoris or myocardial infarction due to the extent of coronary atherosclerotic block than individual serum ADMA levels .

Entities:  

Keywords:  Asymmetric dimethyl arginine(ADMA); Coronary artery disease(CAD); Nitric oxide (NO)

Year:  2014        PMID: 25302189      PMCID: PMC4190709          DOI: 10.7860/JCDR/2014/7849.4665

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  18 in total

1.  Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine.

Authors:  V P Valkonen; H Päivä; J T Salonen; T A Lakka; T Lehtimäki; J Laakso; R Laaksonen
Journal:  Lancet       Date:  2001 Dec 22-29       Impact factor: 79.321

Review 2.  Critical review of unstable angina and non-ST elevation myocardial infarction.

Authors:  P J Sheridan; D C Crossman
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

3.  Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice.

Authors:  P J Kuhlencordt; R Gyurko; F Han; M Scherrer-Crosbie; T H Aretz; R Hajjar; M H Picard; P L Huang
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

4.  Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events.

Authors:  Tanja K Krempl; Renke Maas; Karsten Sydow; Thomas Meinertz; Rainer H Böger; Jan Kähler
Journal:  Eur Heart J       Date:  2005-04-28       Impact factor: 29.983

5.  Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study).

Authors:  Andreas Meinitzer; Ursula Seelhorst; Britta Wellnitz; Gabriele Halwachs-Baumann; Bernhard O Boehm; Bernhard R Winkelmann; Winfried März
Journal:  Clin Chem       Date:  2006-12-21       Impact factor: 8.327

6.  Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method.

Authors:  N K Cortas; N W Wakid
Journal:  Clin Chem       Date:  1990-08       Impact factor: 8.327

7.  Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction.

Authors:  Marianne Zeller; Claudia Korandji; Jean-Claude Guilland; Pierre Sicard; Catherine Vergely; Luc Lorgis; Jean-Claude Beer; Laurence Duvillard; Anne-Cécile Lagrost; Daniel Moreau; Philippe Gambert; Yves Cottin; Luc Rochette
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-14       Impact factor: 8.311

8.  Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.

Authors:  Erdal Cavusoglu; Cyril Ruwende; Vineet Chopra; Sunitha Yanamadala; Calvin Eng; David J Pinsky; Jonathan D Marmur
Journal:  Coron Artery Dis       Date:  2009-03       Impact factor: 1.439

9.  Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.

Authors:  Tse-Min Lu; Yu-An Ding; Shing-Jong Lin; Wen-Shin Lee; Ho-Charng Tai
Journal:  Eur Heart J       Date:  2003-11       Impact factor: 29.983

Review 10.  Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis.

Authors:  Maurício Batista Paes Landim; Antônio Casella Filho; Antônio Carlos Palandri Chagas
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

View more
  7 in total

1.  How does spa treatment affect cardiovascular function and vascular endothelium in patients with generalized osteoarthritis? A pilot study through plasma asymmetric di-methyl arginine (ADMA) and L-arginine/ADMA ratio.

Authors:  Fatih Karaarslan; Kagan Ozkuk; Serap Seringec Karabulut; Seldag Bekpinar; Mufit Zeki Karagulle; Nergis Erdogan
Journal:  Int J Biometeorol       Date:  2017-12-07       Impact factor: 3.787

2.  Asymmetric Dimethylarginine Predicts Long-Term Outcome in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Alaadin Vögeli; Manuel Ottiger; Marc A Meier; Christian Steuer; Luca Bernasconi; Andreas Huber; Mirjam Christ-Crain; Christoph Henzen; Claus Hoess; Robert Thomann; Werner Zimmerli; Beat Mueller; Philipp Schuetz
Journal:  Lung       Date:  2017-08-29       Impact factor: 2.584

Review 3.  Asymmetric Dimethylarginine and Its Relation As a Biomarker in Nephrologic Diseases.

Authors:  Mustafa E Sitar
Journal:  Biomark Insights       Date:  2016-12-07

4.  Admission levels of asymmetric and symmetric dimethylarginine predict long-term outcome in patients with community-acquired pneumonia.

Authors:  Alaadin Vögeli; Manuel Ottiger; Marc A Meier; Christian Steuer; Luca Bernasconi; Prasad Kulkarni; Andreas Huber; Mirjam Christ-Crain; Christoph Henzen; Claus Hoess; Robert Thomann; Werner Zimmerli; Beat Mueller; Philipp Schuetz
Journal:  Respir Res       Date:  2017-01-23

5.  Evaluation of serum Asymmetric Dimethyl Arginine concentrations in coronary artery disease patients without traditional cardiovascular risk factors.

Authors:  Majid Ghayour-Mobarhan; Nayyereh Ayati; Amirhossein Sahebkar; Mohsen Moohebati; Narjes Ayati; Sepideh Elyasi; Amir Houshang Mohammadpour
Journal:  Acta Biomed       Date:  2018-06-07

6.  Arginine and Arginine/ADMA Ratio Predict 90-Day Mortality in Patients with Out-of-Hospital Cardiac Arrest-Results from the Prospective, Observational COMMUNICATE Trial.

Authors:  Annalena Keller; Christoph Becker; Katharina Nienhaus; Katharina Beck; Alessia Vincent; Raoul Sutter; Kai Tisljar; Philipp Schuetz; Luca Bernasconi; Peter Neyer; Hans Pargger; Stephan Marsch; Sabina Hunziker
Journal:  J Clin Med       Date:  2020-11-25       Impact factor: 4.241

Review 7.  Understanding the Causes and Implications of Endothelial Metabolic Variation in Cardiovascular Disease through Genome-Scale Metabolic Modeling.

Authors:  Sarah McGarrity; Haraldur Halldórsson; Sirus Palsson; Pär I Johansson; Óttar Rolfsson
Journal:  Front Cardiovasc Med       Date:  2016-04-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.